{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-006344","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2026-08-13T20:15:36+00:00","discovered_at":"2026-08-13T20:17:00.366531+00:00","generated_at":"2026-08-13T20:17:32.018854+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aethlon Medical reports Q1 FY2027 results; cash $4.9M, raises $4M post-quarter","bullets":["Cash and cash equivalents ~$4.9M as of June 30, 2026; raised ~$4.0M gross in public offering after quarter-end.","Operating expenses decreased 11.9% to ~$1.6M vs $1.8M in prior-year quarter.","First participant dosed in third/final cohort of Phase 1 oncology study in Australia; early biomarker signals support Hemopurifier.","Long COVID manuscript accepted for publication in International Journal of Molecular Sciences.","Company believes cash resources sufficient to fund operations for at least next 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-006344","json":"https://secwatch.observer/filing/0001683168-26-006344.json","markdown":"https://secwatch.observer/filing/0001683168-26-006344.md","text":"https://secwatch.observer/filing/0001683168-26-006344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316826006344/0001683168-26-006344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316826006344/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:17:32.018854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}